Ethris is a biopharmaceutical company focused on developing therapies for pulmonary diseases such as primary ciliary dyskinesia. It provides the Stabilized Non-Immunogenic mRNA (SNIM RNA) technology platform based on stabilized non-immunogenic mRNAs, which evade the innate immune system leading to sustained production of therapeutically active proteins within the human body.